**		PAIDC
QUERY CONTROL FORM		RTIS USE ONLY
Application No. 10 055 842	Prepared by NH	Tracking Number 05914314
Examiner-GAU Tones - 1616	Date 10/28/04 3-31-4	Week Date 03/01/04
	No. of queries	IFW

JACKET					
a. Serial No.	f. Foreign Priority	k. Print Claim(s)	PTO-1449		
b. Applicant(s)	g. Disclaimer	I. Print Fig.	q. PTOL-85b		
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract		
d. PCT	i. Title	n. PTO-270/328	s. Sheets/Figs		
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other		
	<u> </u>				

MESSAGE
PTO-1449: Please either initial or line
through citations. Copy provided for reference
Markyan
initials NH
RESPONSE
initials



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

USSN:

10/055,842

Date Filed:

January 23, 2002

ACEG 900A

1. BY APPLICANT

1. pplicant: Gale, N.W., et al.

Title: Methods of Imaging and Targeting Vasculature

1. pp. Tebruary 6, 2003

MENT

Examiner:

*

Not yet known

U.S. PATENT DOCUMENTS

Examiner **Initials**

Patent Number

Issue <u>Date</u>

Publication Number

Publication **Date**

Name

FOREIGN PATENT DOCUMENTS

Examiner **Initials**

Document

Number

Date

Country

Class/

Translation Date Subclass

No <u>Yes</u>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	Kirsch, JE, 1991, "Basic principles of magnetic resonance contrast agents", Top Magn Reson Imaging 3:1-18
	Wallis, F. and Gilbert, FJ, 1999, J R, "Magnetic resonance imaging in oncology: an overview", Coll Surg Edinb 44:117-125
	Schiepers, C. and Hoh, CK, 1998, "Positron emission tomography as a diagnostic tool in oncology", Eur Radiol 8:1481-1494
-	Ferrand, SK, et al., 1999, "What is new in nuclear medicine imaging?", Surg Oncol Clin N Am 8:185-204
	Wang, H.U., et al., 1998, "Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4", Cell 93:741-753.

...Information Disclosure Statement Form 1449 Gales N. W., et al. -SUSSN 10/055,842

Gerety, S.S., et a EphB4 and its spe development", M	l., 1999, "Symmetrical mutant phenotypes of the rec cific transmembrane ligand ephrin-B2 in cardiovasc ol Cell 4:403-414.	eptor ular
cardiovascular d	al., 1999, "Roles of ephrinB ligands and EphB receptor velopment: demarcation of arterial/venous domain genesis, and sprouting angiogenesis", Genes & Dev	ıs,
EXAMINER CONSIDERED	DATE	

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:

Linda O. Palladino / Reg. No. 45,636

Agent for Applicants

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road Tarrytown, New York 10591 (914) 345-7400